Načítá se...
NLRC5, a promising new entry in tumor immunology
The recent use of T cell-based cancer immunotherapies, such as adoptive T-cell transfer and checkpoint blockade, yields increasing clinical benefit to patients with different cancer types. However, decrease of MHC class I expression is a common mechanism transformed cells take advantage of to evade...
Uloženo v:
| Vydáno v: | J Immunother Cancer |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4950760/ https://ncbi.nlm.nih.gov/pubmed/27437103 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-016-0143-z |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|